BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-11-29 11:21 |
BerGenBio to Present at the 3rd Nordic-American Life Science Conference in New …
|
English | 3.1 KB | ||
| 2018-11-21 14:02 |
BerGenBio appoints cancer drug development specialist Alan Barge MD as interim …
|
English | 5.5 KB | ||
| 2018-11-13 06:00 |
BerGenBio ASA: Results for the Third Quarter 2018
|
English | 3.6 MB | ||
| 2018-11-13 06:00 |
BerGenBio ASA: Results for the Third Quarter 2018
|
English | 1.5 MB | ||
| 2018-11-13 06:00 |
BerGenBio ASA: Results for the Third Quarter 2018
|
English | 59.8 KB | ||
| 2018-11-13 06:00 |
BerGenBio ASA: Results for the Third Quarter 2018
|
English | 8.0 KB | ||
| 2018-11-06 13:15 |
BerGenBio reports ~80% improvement in PFS of AXL-positive vs AXL-negative NSCLC…
|
English | 11.1 KB | ||
| 2018-11-06 06:00 |
BerGenBio ASA: Invitation to Third Quarter 2018 Results Presentation and Webcast
|
English | 2.1 KB | ||
| 2018-11-05 06:00 |
BerGenBio ASA: Share options to primary insiders
|
English | 1.7 KB | ||
| 2018-11-02 06:00 |
BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in…
|
English | 6.6 KB | ||
| 2018-10-22 05:00 |
BerGenBio announces interim biomarker and phase II clinical data with selective…
|
English | 8.7 KB | ||
| 2018-10-09 07:00 |
BerGenBio to present interim phase II clinical, preclinical and biomarker data …
|
English | 6.7 KB | ||
| 2018-10-08 11:25 |
Shareholder disclosure
|
English | 586 bytes | ||
| 2018-10-05 15:00 |
BerGenBio ASA (OSE:BGBIO): 5 October 2018 - Responsibility Statement for First …
|
English | 33.3 KB | ||
| 2018-10-05 15:00 |
BerGenBio ASA (OSE:BGBIO): 5 October 2018 - Responsibility Statement for First …
|
English | 883 bytes |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
